Terms: = Skin cancer AND MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7 AND Clinical Outcome
12 results:
1. CCR4-positive peripheral T-cell lymphoma presenting as eosinophilic pneumonia and developing from prolonged pustular psoriasis.
Sekiguchi N; Komatsu M; Ichiyama T; Kobayashi A; Gomi D; Fukushima T; Kobayashi T; Noguchi T; Nakazawa H; Asano N; Ishida F; Koizumi T
J Int Med Res; 2021 Feb; 49(2):300060521996165. PubMed ID: 33641488
[TBL] [Abstract] [Full Text] [Related]
2. Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.
Mochizuki Y; Tazawa H; Demiya K; Kure M; Kondo H; Komatsubara T; Sugiu K; Hasei J; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Immunol Immunother; 2021 May; 70(5):1405-1417. PubMed ID: 33151368
[TBL] [Abstract] [Full Text] [Related]
3. Immunohistochemical CD271 expression correlates with melanoma progress in a case-control study.
Nielsen PS; Riber-Hansen R; Steiniche T
Pathology; 2018 Jun; 50(4):402-410. PubMed ID: 29678478
[TBL] [Abstract] [Full Text] [Related]
4. Intralesional anti-cd20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
Eberle FC; Holstein J; Scheu A; Fend F; Yazdi AS
J Dtsch Dermatol Ges; 2017 Mar; 15(3):319-323. PubMed ID: 28177583
[TBL] [Abstract] [Full Text] [Related]
5. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.
Garg K; Maurer M; Griss J; Brüggen MC; Wolf IH; Wagner C; Willi N; Mertz KD; Wagner SN
Hum Pathol; 2016 Aug; 54():157-64. PubMed ID: 27107457
[TBL] [Abstract] [Full Text] [Related]
6. CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans.
Thomas-Pfaab M; Annereau JP; Munsch C; Guilbaud N; Garrido I; Paul C; Brousset P; Lamant L; Meyer N
J Dermatol Sci; 2013 Feb; 69(2):105-13. PubMed ID: 23219141
[TBL] [Abstract] [Full Text] [Related]
7. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts.
Meyer S; Fuchs TJ; Bosserhoff AK; Hofstädter F; Pauer A; Roth V; Buhmann JM; Moll I; Anagnostou N; Brandner JM; Ikenberg K; Moch H; Landthaler M; Vogt T; Wild PJ
PLoS One; 2012; 7(6):e38222. PubMed ID: 22685558
[TBL] [Abstract] [Full Text] [Related]
8. Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells.
Felcht M; Heck M; Weiss C; Becker JC; Dippel E; Müller CS; Nashan D; Sachse MM; Nicolay JP; Booken N; Goerdt S; Klemke CD
Br J Dermatol; 2012 Aug; 167(2):348-58. PubMed ID: 22512270
[TBL] [Abstract] [Full Text] [Related]
9. Reassessment of diagnostic criteria in cutaneous lymphocytic infiltrates.
Cotta AC; Cintra ML; de Souza EM; Magna LA; Vassallo J
Sao Paulo Med J; 2004 Jul; 122(4):161-5. PubMed ID: 15543371
[TBL] [Abstract] [Full Text] [Related]
10. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma.
Aklilu M; Stadler WM; Markiewicz M; Vogelzang NJ; Mahowald M; Johnson M; Gajewski TF
Ann Oncol; 2004 Jul; 15(7):1109-14. PubMed ID: 15205206
[TBL] [Abstract] [Full Text] [Related]
11. Systemic therapy with cyclophosphamide and anti-cd20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.
Fierro MT; Savoia P; Quaglino P; Novelli M; Barberis M; Bernengo MG
J Am Acad Dermatol; 2003 Aug; 49(2):281-7. PubMed ID: 12894078
[TBL] [Abstract] [Full Text] [Related]
12. Morphometric analysis of AgNORs in uveal malignant melanoma.
Staibano S; Orabona P; Mezza E; Salvatore G; Tranfa F; Capone D; Errico ME; Bonavolontà G; Lucariello A; De Rosa G
Anal Quant Cytol Histol; 1998 Dec; 20(6):483-92. PubMed ID: 9870100
[TBL] [Abstract] [Full Text] [Related]
